Sean McGowan on What’s in Store for Biosimilars in 2021 and Beyond
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, discusses how 2020 has affected biosimilar development and his predictions for the industry going forward.
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, recently appeared during a series of interviews on MJH Life Sciences™’ Medical World News about the challenges of bringing a biosimilar to market, how to ensure biosimilar competition in the future, and what to keep an eye on as the market grows over time. Today, we are bringing you the first part of that discussion, which focuses on McGowan’s thoughts on how 2020 has shaped biosimilar progress and his main predictions for the future of the biosimilars industry.
To watch the full first part of this interview, click here.
To watch part 2 of this interview, click here.
To watch part 3 of this interview, click here.
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
How Health Policy Can Impact Adoption for Adalimumab Biosimilars
September 25th 2022In this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, discussed current policy initiatives that could help biosimilar adoption and how the Inflation Reduction Act is expected to influence the adalimumab market.
Not So Different: Kathy Oubre on What Oncology Practices Have Lacked During the Pandemic
October 18th 2020We sat down with Kathy Oubre, chief operating officer at the Pontchartrain Cancer Center, to discuss what practices have had to forgo during the coronavirus disease 2019 (COVID-19) crisis and how biosimilar access has been affected.
